Reagila is indicated for the treatment of schizophrenia in adult patients. The approved dose range of Reagila for the treatment of schizophrenia in adult patients is 1.5-6 mg/d. The starting dose of Reagila is 1.5 mg once daily. Reagila is for oral use, to be taken once daily with or without food.

REAGILA® (cariprazine) delivers simultaneous efficacy on both the positive and negative symptoms of schizophrenia and prevents relapse in the long term. REAGILA was tested in two different patient populations with schizophrenia

The mechanism of action of cariprazine is complex. Its affinity for dopamine D3 receptors and action on 5HT1A, 5HT2A and alpha1B receptors differentiate it pharmacologically from other antipsychotics drugs.

Dopamine is a diverse and important neurotransmitter in the human body. Although it is typically thought of as our “reward and salience” neurotransmitter, it plays a role in controlling different functions including cognition, emotion, hormone regulation, voluntary motor movements, and positive reinforcement,… within its four major pathways.